Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients

References

• Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018;96(6):1–17.
   Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1–S201.
   PubMed Web of Science ®Google Scholar
• Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2008;19(2):213–216.
   PubMed Web of Science ®Google Scholar
• Basutkar RS, Varghese R, Mathew NK, et al. Systematic review and meta-analysis of potential pleiotropic effects of sevelamer in chronic kidney disease: beyond phosphate control. Nephrology (Carlton). 2022;27(4):337–354.
   PubMed Web of Science ®Google Scholar
• Lopes AA, Tong L, Thumma J, et al. Phosphate binder use and mortality among hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis. 2012;60(1):90–101.
   PubMed Web of Science ®Google Scholar
• Floege J. Phosphate binders in chronic kidney disease: a systematic review of recent data. J Nephrol. 2016;29(3):329–340.
   PubMed Web of Science ®Google Scholar
• St Peter WL, Fan Q, Weinhandl E, et al. Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for medicare & medicaid services data. Clin J Am Soc Nephrol. 2009;4(12):1954–1961.
   PubMed Web of Science ®Google Scholar
• Erratum: kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO. Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) (2017). Kidney Int Suppl. 2017;7:1–59.
   Google Scholar
• Ikee R, Tsunoda M, Sasaki N, et al. Emerging effects of sevelamer in chronic kidney disease. Kidney Blood Press Res. 2013;37(1):24–32.
   PubMed Web of Science ®Google Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–784.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926.
   PubMed Web of Science ®Google Scholar
• Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–394.
   PubMed Web of Science ®Google Scholar
• Schünemann HJ, Oxman AD, Higgins JP, et al. Chapter 12: interpreting results and drawing conclusions. In: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. London: The Cochrane Collaboration; 2011.
   Google Scholar
• Ferreira A, Frazão JM, Monier-Faugere MC, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008;19(2):405–412.
   PubMed Web of Science ®Google Scholar
• Di Iorio B, Molony D, Bell C, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis. 2013;62(4):771–778.
   PubMed Web of Science ®Google Scholar
• Wei C, Yan H, Cai X, et al. Effects of low-dose calcitriol combined with sevelamer carbonate in delaying vascular calcification in patients undergoing maintenance hemodialysis. Clin Misdiagn Misther. 2020;33:45–50.
   Google Scholar
• Huang C. Effect of sevelamer hydrochloride on hyperphosphatemia in maintenance hemodialysis patients with nephropathy. Contemp Med. 2014;20:68–69.
   Google Scholar
• Li C, Zhang J, Bai Y, et al. Clinical observation of sevelamer in treatment of hyperphosphatemia in maintenance hemodialysis. Drug Clin. 2020;35:1200–1203.
   Google Scholar
• He D, Lu Z, Lu J. Effect of sevelamer carbonate on microinflammation and prognosis in patients with chronic renal failure complicated with hyperphosphatemia. Hebei Med. 2019;25:1850–1854.
   Google Scholar
• Shaheen FA, Akeel NM, Badawi LS, et al. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Saudi Med J. 2004;25(6):785–791.
   PubMed Web of Science ®Google Scholar
• Fanghua G. Comparison of the clinical efficacy and safety of sevelamer carbonate and calcium carbonate in the treatment of chronic kidney disease hyperphosphatemia. Chin J Clin Rational Drug Use. 2021;14:92–94.
   Google Scholar
• Koiwa F, Onoda N, Kato H, et al. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial. 2005;9(4):340–346.
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis. 1997;29(1):66–71.
   PubMed Web of Science ®Google Scholar
• Asmus HG, Braun J, Krause R, et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant. 2005;20(8):1653–1661.
   PubMed Web of Science ®Google Scholar
• Zhou H, Feng Y, Jia X, et al. The effect of sevelamer hydrochloride on hyperphosphatemia in chronic renal failure patients on maintenance hemodialysis. Chin J Blood Purif. 2015;14:608–611.
   Google Scholar
• Lin HH, Liou HH, Wu MS, et al. Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum klotho levels in chronic haemodialysis patients. Nephrology (Carlton). 2014;19(11):672–678.
   PubMed Web of Science ®Google Scholar
• Su H, Zeng L, Wang L. Effect of sevelamer carbonate on serum phosphorus, calcium and inflammatory reaction in patients with chronic renal insufficiency and hyperphosphatemia. Med Innov Chin. 2018;15:38–41.
   Google Scholar
• Zhang H, Mao Y, Xu H, et al. Clinical trial of sevelamer carbonate in the treatment of patients with maintenance hemodialysis. Chin J Clin Pharmacol. 2021;56:70–71.
   Google Scholar
• Zheng H, Liu Z. The use of sevelamer carbonate in the treatment of chronic kidney disease patients with hyperphosphatemia. Shandong Med. 2016;56:70–71.
   Google Scholar
• Jia Zhen T. Comparative study of sevelamer hydrochloride and calcium carbonate in the treatment of end-stage renal disease with maintenance hemodialysis hyperphosphatemia. J Clin Med. 2018;5:114–117.
   Google Scholar
• Lin J, Zeng T, Wang R. Effect of svilam carbonate tablets on the level of calcium and phosphorus in maintenance hemodialysis patients with chronic renal failure. Chin J Dial Artif Organs. 2018;29:3–4–7.
   Google Scholar
• Zhao J, Chen X, Zhang J, et al. Effect of sevelamer hydrochloride on serum phosphorus in uremia patients with secondary hyperparathyroidism using calcitriol pulse therapy. Hainan Med J. 2012;23:37–38.
   Google Scholar
• Yang J. Efficacy of sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic renal failure undergoing maintenance hemodialysis. Strait Pharm J. 2021;33:150–152.
   Google Scholar
• Liu L, Qiu H. Effect of sevelamer carbonate on parameters of chronic kidney disease mineral bone disorder in dialysis patients. Chin Prescript Drugs. 2021;19:86–87.
   Google Scholar
• Yu Q, Zeng J, Wu H. Clinical effect of sviram carbonate combined with calcitriol in the treatment of uremia complicated with secondary hyperparathyroidism. Forum Prim Care Med. 2020;24:4203–4204.
   Google Scholar
• Zhang Q, Peng W, Ouyang F, et al. Efficacy and safety of sevelamer and calcium carbonate D3 in regulating calcium and phosphorus levels in maintenance hemodialysis patients with chronic renal failure. Mod Chin Doct. 2020;58:50–53.
   Google Scholar
• Lan S, Zhang G. Effectiveness of sevelamer on hyperphosphatemia in chronic renal failure patients with maintenance hemodialysis and its influence on inflammatory factors. Med Innov Chin. 2018;15:142–145.
   Google Scholar
• Takei T, Otsubo S, Uchida K, et al. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. Nephron Clin Pract. 2008;108(4):c278–283.
   PubMedGoogle Scholar
• Kakuta T, Tanaka R, Hyodo T, et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis. 2011;57(3):422–431.
   PubMed Web of Science ®Google Scholar
• Filiopoulos V, Koutis I, Trompouki S, et al. Lanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patients. Ther Apher Dial. 2011;15(1):20–27.
   PubMed Web of Science ®Google Scholar
• Prajapati VA, Galani VJ, Shah PR. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis. Saudi J Kidney Dis Transpl. 2014;25(3):530–538.
   PubMedGoogle Scholar
• Cheng X, Bai Y. Effect of sevelamer on maintenance hemodialysis patients with secondary hyperparathyroidism. Anhui Med J. 2019;40:933–935.
   Google Scholar
• Chen Y, Zhang Y, Yao X, et al. Observation on the efficacy of different medication regimens on secondary hyperparathyroidism in hemodialysis patients. Mod Chin Doct. 2021;59:39–43.
   Google Scholar
• Yan H. End-stage renal disease maintenance hemodialysis to take the carbonic acid sevelamer treatment on its effectiveness of hyperphosphatemia. J Northern Pharm. 2019;16:177–178.
   Google Scholar
• Zhang Y. Analysis of short-term efficacy of sevelame hydrochloride in the treatment of hyperphosphatemia in maintenance hemodialysis patients. J Chin Prescript Drug. 2017;15:82–83.
   Google Scholar
• Li Y, Lin Z, Cai Z. The comparative analysis of two kinds 0f phosphate binder in the treatment of maintenance hemodialysis patients with hyperphosphatemia. J Chin Prescript Drug. 2014;12:12–13.
   Google Scholar
• Zhe J, Chen J, Rong C. Effect of sevelamer carbonate on the clinical efficacy of chronic kidney disease-mineral and bone disorder in the patients with maintenance hemodialysis. For Primary Care Med. 2021;25:1806–1808.
   Google Scholar
• Ammirati AL, Dalboni MA, Cendoroglo M, et al. Coronary artery calcification, systemic inflammation markers and mineral metabolism in a peritoneal dialysis population. Nephron Clin Pract. 2006;104(1):c33–40.
   PubMedGoogle Scholar
• Sprague SM. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin. 2007;23(12):3167–3175.
   PubMed Web of Science ®Google Scholar
• London GM, Marty C, Marchais SJ, et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004;15(7):1943–1951.
   PubMed Web of Science ®Google Scholar
• Liabeuf S, Ryckelynck JP, El Esper N, et al. Randomized clinical trial of sevelamer carbonate on serum klotho and fibroblast growth factor 23 in CKD. Clin J Am Soc Nephrol. 2017;12(12):1930–1940.
   PubMed Web of Science ®Google Scholar
• Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607–617.
   PubMed Web of Science ®Google Scholar
• Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2004;44(2):34–38.
   PubMedGoogle Scholar
• Stevens LA, Djurdjev O, Cardew S, et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol. 2004;15(3):770–779.
   PubMed Web of Science ®Google Scholar
• Raggi P, Vukicevic S, Moysés RM, et al. Ten-year experience with sevelamer and calcium salts as phosphate binders. Clin J Am Soc Nephrol. 2010;5(1):S31–S40.
   PubMedGoogle Scholar
• Felsenfeld AJ, Levine BS, Rodriguez M. Pathophysiology of calcium, phosphorus, and magnesium dysregulation in chronic kidney disease. Semin Dial. 2015;28(6):564–577.
   PubMed Web of Science ®Google Scholar
• Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16(7):2205–2215.
   PubMed Web of Science ®Google Scholar
• Scialla JJ, Wolf M. Roles of phosphate and fi-broblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol. 2014;10(5):268–278.
   PubMed Web of Science ®Google Scholar
• Olauson H, Vervloet MG, Cozzolino M, et al. New insights into the FGF23-Klotho axis. Semin Nephrol. 2014;34(6):586–597.
   PubMed Web of Science ®Google Scholar
• Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) study. J Am Soc Nephrol. 2007;18(9):2600–2608.
   PubMed Web of Science ®Google Scholar
• Stack AG, Bloembergen WE. A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. Am J Kidney Dis. 2001;38(5):992–1000.
   PubMed Web of Science ®Google Scholar
• Ruospo M, Palmer SC, Natale P, et al. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2018;8(8):Cd006023.
   PubMedGoogle Scholar
• Bogin E, Massry SG, Harary I. Effect of Para-thyroid hormone on rat heart cells. J Clin Invest. 1981;67(4):1215–1227.
   PubMed Web of Science ®Google Scholar
• Tastan I, Schreckenberg R, Mufti S, et al. Parathyroid hormone improves contractile performance of adult rat ventricular cardiomyocytes at low concentrations in a non-acute way. Cardiovasc Res. 2009;82(1):77–83.
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Ito M, Segawa H, et al. Secondary hyperparathyroidism and phosphate sensing in parathyroid glands. J Med Invest. 2000;47:118–122.
   PubMedGoogle Scholar
• Geng Y, Mosyak L, Kurinov I, et al. Structural mechanism of ligand activation in human calcium-sensing receptor. eLife. 2016;5:e13662.
   PubMed Web of Science ®Google Scholar
• Ferramosca E, Burke S, Chasan-Taber S, et al. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J. 2005;149(5):820–825.
   PubMed Web of Science ®Google Scholar
• Habbous S, Przech S, Acedillo R, et al. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant. 2017;32(1):111–125.
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Dillon MA, et al. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant. 1999;14(12):2907–2914.
   PubMed Web of Science ®Google Scholar
• Lee BT, Ahmed FA, Hamm LL, et al. Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease. BMC Nephrol. 2015;16:77.
   PubMed Web of Science ®Google Scholar
• Shantouf R, Budoff MJ, Ahmadi N, et al. Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients. Am J Nephrol. 2008;28(2):275–279.
   PubMed Web of Science ®Google Scholar
• Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342(20):1478–1483.
   PubMed Web of Science ®Google Scholar
• Guérin AP, London GM, Marchais SJ, et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000;15(7):1014–1021.
   PubMed Web of Science ®Google Scholar
• Adeney KL, Siscovick DS, Ix JH, et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol. 2009;20(2):381–387.
   PubMed Web of Science ®Google Scholar
• Elder GJ, Center J. The role of calcium and non calcium-based phosphate binders in chronic kidney disease. Nephrology (Carlton, Vic). 2017;22:42–46.
   PubMed Web of Science ®Google Scholar
• Guerin AP, Blacher J, Pannier B, et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation. 2001;103(7):987–992.
   PubMed Web of Science ®Google Scholar
• Phannajit J, Wonghakaeo N, Takkavatakarn K, et al. The impact of phosphate lowering agents on clinical and laboratory outcomes in chronic kidney disease patients: a systematic review and meta-analysis of randomized controlled trials. J Nephrol. 2022;35(2):473–491.
   PubMed Web of Science ®Google Scholar